Canna Law Blog

JANUARY 6, 2023

The year 2022 was a busy one for the California cannabis industry, with everything from tax reform to the beginning of enforcement. Probably the biggest complaint our California cannabis team hears is just how bad of a job the state has done in terms of letting the illegal market fester. California hints at enforcement?

Collective 73

Collective Hemp Cannabis Programs 73

MMJ Recs

AUGUST 29, 2022

Missouri dispensaries are now selling high-quality, locally produced marijuana products to hundreds of thousands of Missouri MMJ patients. Missouri medical marijuana patients get to shop (as well as browse and learn) at some of the best MMJ dispensaries in the country. Can Out-Of-State Cardholders Buy Medical Marijuana In Missouri?

Dispensary 52

Dispensary Patients Treatment Education 52

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. Most importantly, you will be responsible for the dynamic work of ensuring state-level legal access to FDA-approved psychedelic medications, beginning with MDMA for the treatment of PTSD. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

FEBRUARY 26, 2022

The organization has, they say, ……evaluated patient access, affordability, equity, and product safety. With a decline in legislative improvements in state medical cannabis programs, millions of patients are left with limited or no access,” ASA Executive Director Debbie Churgai said. “It

Access 98

Access Law Patients Programs 98

Cannabis Law Report

MAY 25, 2022

Barbuto informed her to-be supervisor at ASM that she was a qualifying medical marijuana patient under Massachusetts law, adding that she did not take the medical marijuana before work or at work. Barbuto’s supervisor informed her that her lawful use of medical marijuana would not be a problem for ASM. 2] Barbuto , p.

Policy 52

Policy Safety Law Patients 52

Veriheal

JUNE 21, 2023

If approved by the Food and Drug Administration (FDA), this psychedelic would be used to treat chronic and life-threatening mental disorders, especially for patients with limited access to effective treatments. Federal laws currently classify psilocybin as a Schedule I drug alongside addictive drugs like cocaine and fentanyl.

Access 97

Access Legalization Research and Development Legislation 97